日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia

在针对华氏巨球蛋白血症的布鲁顿酪氨酸激酶抑制剂的3期ASPEN研究中,周围神经病变

Heyman, Benjamin M; Opat, Stephen S; Wahlin, Björn E; Dimopoulos, Meletios-Athanasios C; Castillo, Jorge J; Tedeschi, Alessandra; Tam, Constantine S; Buske, Christian; Owen, Roger G; Leblond, Véronique; Trotman, Judith; Barnes, Gisoo; Chan, Wai Y; Schneider, Jingjing; Allewelt, Heather; Cohen, Aileen; Matous, Jeffrey V

Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study

ASPEN 研究中,华氏巨球蛋白血症患者从伊布替尼过渡到泽布替尼后的疗效

García-Sanz, Ramón; Owen, Roger G; Jurczak, Wojciech; Dimopoulos, Meletios A; McCarthy, Helen; Cull, Gavin; Opat, Stephen S; Castillo, Jorge J; Kersten, Marie José; Wahlin, Björn E; Grosicki, Sebastian; Prathikanti, Radha; Tian, Tian; Allewelt, Heather; Cohen, Aileen Cleary; Tam, Constantine S

Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia

ASPEN 研究的生物标志物分析比较了泽布替尼和伊布替尼治疗华氏巨球蛋白血症患者的疗效

Tam, Constantine S; Opat, Stephen; D'Sa, Shirley; Jurczak, Wojciech; Lee, Hui-Peng; Cull, Gavin; Owen, Roger G; Marlton, Paula; Wahlin, Björn E; García-Sanz, Ramón; McCarthy, Helen; Mulligan, Stephen; Tedeschi, Alessandra; Castillo, Jorge J; Czyż, Jarosław; Fernández De Larrea, Carlos; Belada, David; Libby, Edward; Matous, Jeffrey; Motta, Marina; Siddiqi, Tanya; Tani, Monica; Trněný, Marek; Minnema, Monique C; Buske, Christian; Leblond, Véronique; Treon, Steven P; Trotman, Judith; Wu, Binghao; Yu, Yiling; Shen, Zhirong; Chan, Wai Y; Schneider, Jingjing; Allewelt, Heather; Cohen, Aileen; Dimopoulos, Meletios A

Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial

Waldenström巨球蛋白血症患者的健康相关生活质量:ASPEN试验结果

Tedeschi, Alessandra; Tam, Constantine S; Owen, Roger G; Buske, Christian; Leblond, Véronique; Dimopoulos, Meletios; Garcia-Sanz, Ramón; Castillo, Jorge J; Trotman, Judith; Treon, Steven P; Yang, Keri; Tang, Boxiong; Allewelt, Heather; Patel, Sheel; Chan, Wai Y; Cohen, Aileen; Chen, Shengnan; Barnes, Gisoo

Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study

扎那布替尼与伊布替尼治疗症状性华氏巨球蛋白血症:来自随机 III 期 ASPEN 研究的最终分析

Dimopoulos, Meletios A; Opat, Stephen; D'Sa, Shirley; Jurczak, Wojciech; Lee, Hui-Peng; Cull, Gavin; Owen, Roger G; Marlton, Paula; Wahlin, Björn E; Garcia-Sanz, Ramon; McCarthy, Helen; Mulligan, Stephen; Tedeschi, Alessandra; Castillo, Jorge J; Czyz, Jaroslaw; Fernández de Larrea, Carlos; Belada, David; Libby, Edward; Matous, Jeffrey; Motta, Marina; Siddiqi, Tanya; Tani, Monica; Trněný, Marek; Minnema, Monique C; Buske, Christian; Leblond, Veronique; Treon, Steven P; Trotman, Judith; Chan, Wai Y; Schneider, Jingjing; Allewelt, Heather; Patel, Sheel; Cohen, Aileen; Tam, Constantine S

Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial

对新诊断的、适合和不适合移植的多发性骨髓瘤患者进行来那度胺维持治疗;对接受 XI 试验治疗的 4358 例患者进行第二原发性恶性肿瘤的分析

Jones, John R; Cairns, David A; Menzies, Tom; Pawlyn, Charlotte; Davies, Faith E; Sigsworth, Rachel; Brioli, Annamaria; Jenner, Matthew W; Kaiser, Martin F; Olivier, Catherine; Reed, Molly; Drayson, Mark T; Owen, Roger G; Boyd, Kevin D; Cook, Gordon; Morgan, Gareth J; Jackson, Graham H

The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open-label, randomised, phase III trial

在来那度胺维持治疗的基础上加用伏立诺他治疗所有年龄段新诊断的多发性骨髓瘤患者:来自“Myeloma XI”多中心、开放标签、随机、III期试验的结果

Jenner, Matthew W; Pawlyn, Charlotte; Davies, Faith E; Menzies, Tom; Hockaday, Anna; Olivier, Catherine; Jones, John R; Karunanithi, Kamaraj; Lindsay, Jindriska; Kishore, Bhuvan; Cook, Gordon; Drayson, Mark T; Kaiser, Martin F; Owen, Roger G; Gregory, Walter; Cairns, David A; Morgan, Gareth J; Jackson, Graham H

Copy number evolution and its relationship with patient outcome-an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial

拷贝数演变及其与患者预后的关系——来自 Myeloma XI 试验的 178 对匹配的初诊-复发肿瘤样本的分析

Croft, James; Ellis, Sidra; Sherborne, Amy L; Sharp, Kim; Price, Amy; Jenner, Matthew W; Drayson, Mark T; Owen, Roger G; Chown, Sally; Lindsay, Jindriska; Karunanithi, Kamaraj; Hunter, Hannah; Gregory, Walter M; Davies, Faith E; Morgan, Gareth J; Cook, Gordon; Atanesyan, Lilit; Savola, Suvi; Cairns, David A; Jackson, Graham; Houlston, Richard S; Kaiser, Martin F

Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial

卡非佐米、来那度胺、地塞米松和环磷酰胺(KRdc)作为适合移植的新诊断多发性骨髓瘤患者(骨髓瘤XI+)的诱导治疗:一项开放标签随机对照试验的中期分析

Jackson, Graham H; Pawlyn, Charlotte; Cairns, David A; de Tute, Ruth M; Hockaday, Anna; Collett, Corinne; Jones, John R; Kishore, Bhuvan; Garg, Mamta; Williams, Cathy D; Karunanithi, Kamaraj; Lindsay, Jindriska; Rocci, Alberto; Snowden, John A; Jenner, Matthew W; Cook, Gordon; Russell, Nigel H; Drayson, Mark T; Gregory, Walter M; Kaiser, Martin F; Owen, Roger G; Davies, Faith E; Morgan, Gareth J

Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive)

卡非佐米或硼替佐米联合环磷酰胺和地塞米松治疗,随后进行卡非佐米维持治疗,用于治疗既往接受过一种治疗的多发性骨髓瘤患者:一项多中心、II期、随机、对照试验(MUKfive)的结果

Yong, Kwee L; Hinsley, Samantha; Auner, Holger W; Bygrave, Ceri; Kaiser, Martin F; Ramasamy, Karthik; De Tute, Ruth M; Sherratt, Debbie; Flanagan, Louise; Garg, Mamta; Hawkins, Stephen; Williams, Catherine; Cavenagh, Jamie; Rabin, Neil K; Croft, James; Morgan, Gareth; Davies, Faith; Owen, Roger G; Brown, Sarah R